Core Viewpoint - A shareholder has filed a securities class action lawsuit against BlackRock TCP Capital Corp. for alleged misrepresentations regarding the valuation of the Company's investments during a specified period [1][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased or acquired BlackRock securities between November 6, 2024, and January 23, 2026 [1]. - Defendants are accused of making misrepresentations concerning the valuation of the Company's investments [4]. Group 2: Legal Process - Investors wishing to serve as lead plaintiff must file papers by April 6, 2026, and can still share in any recovery without being the lead plaintiff [3]. - All representation in the lawsuit is on a contingency fee basis, meaning shareholders pay no fees or expenses [3]. Group 3: Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since its inception in 1993 and has represented large public and private pension funds [5]. - The firm has been recognized multiple times for its success in litigating class actions [5].

Core Viewpoint - A class action lawsuit has been filed against SLM Corporation (Sallie Mae) for allegedly concealing a significant increase in loan delinquencies during a specific period, leading to investor losses [1][3]. Group 1: Lawsuit Details - The lawsuit represents investors who acquired Sallie Mae securities from July 25, 2025, to August 14, 2025 [1][2]. - The complaint claims that Sallie Mae misled investors about the nature of rising early-stage delinquencies, attributing them to seasonal trends while downplaying the effectiveness of their loss mitigation programs [3]. Group 2: Financial Impact - A TD Cowen report revealed that July delinquencies increased by 49 basis points month-over-month, which was higher than expected for that season [4]. - Following the report, Sallie Mae's stock price fell by $2.67 per share, or 8.09%, closing at $30.32 on August 15, 2025 [4].

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. on behalf of investors who purchased its common stock during the specified class period, alleging misleading statements regarding clinical trial results [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC, representing investors who bought Ultragenyx shares from August 3, 2023, to December 26, 2025 [1][2]. - Investors have until April 6, 2026, to seek appointment as lead plaintiff representative of the class [2]. Group 2: Allegations - The complaint claims that Ultragenyx misled investors by raising expectations about the ORBIT and COSMIC studies, which tested setrusumab for Osteogenesis Imperfecta, while concealing that neither study significantly reduced clinical fracture rates compared to control groups [3]. - Following the disclosure of the study results, Ultragenyx's share price fell from $34.19 on December 26, 2025, to $19.72 on December 29, 2025, representing a decline of over 42% in a single day [3]. Group 3: Company Overview - Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company based in Novato, California, focusing on treatments for rare diseases [2].

Core Viewpoint - A class action lawsuit has been filed against Coupang, Inc. for allegedly misleading investors regarding its cybersecurity practices, leading to significant losses during the specified class period from May 7, 2025, to December 16, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit claims that Coupang's inadequate cybersecurity allowed a former employee to access sensitive customer information for nearly six months without detection [3]. - As a result of the cybersecurity incident, Coupang's CEO resigned, which contributed to the decline in investor confidence and financial losses [3]. Group 2: Investor Information - Investors who purchased Coupang securities during the class period have until February 17, 2026, to seek appointment as lead plaintiff representatives [2]. - Interested investors can contact Berger Montague for more information regarding their rights and the lawsuit [4]. Group 3: Law Firm Background - Berger Montague is a prominent law firm specializing in complex civil litigation and class actions, with a history of recovering over $50 billion for clients [5]. - The firm has achieved more than $2.4 billion in post-trial judgments in 2025 alone, indicating its strong position in the legal field [5].

Core Viewpoint - The Ardent Health class action lawsuit alleges that the company and its executives made misleading statements regarding financial practices and liability reserves, leading to significant stock price declines following revelations of financial mismanagement [3][4]. Group 1: Allegations and Financial Impact - The lawsuit claims that Ardent Health did not rely on accurate methods for determining the collectability of accounts receivable, which inflated reported financial positions [3]. - On November 12, 2025, Ardent Health disclosed a $43 million decrease in third quarter 2025 revenue due to revised accounts receivable assessments, resulting in a nearly 34% drop in stock price [4]. - The company cut its 2025 EBITDA guidance by approximately 9.6%, from a range of $575 million - $615 million to $530 million - $555 million, citing persistent industry-wide cost pressures [4]. Group 2: Class Action Details - Investors who purchased Ardent Health securities between July 18, 2024, and November 12, 2025, can seek appointment as lead plaintiff in the class action lawsuit [1][5]. - The lead plaintiff will represent the interests of all class members and can select a law firm to litigate the case [5]. - Robbins Geller Rudman & Dowd LLP, the firm handling the case, is recognized as a leading complex class action firm with a strong track record in securities fraud litigation [6].

Philadelphia, Pennsylvania--(Newsfile Corp. - February 10, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Richtech Robotics Inc. (NASDAQ: RR) ("Richtech" or the "Company") on behalf of investors who purchased Richtech securities during the period from January 27, 2026 through January 29, 2026 (the "Class Period").Investor Deadline: Investors who purchased Richtech securities during the Class Period may, no later than April 3, 2026, seek ...

Core Viewpoint - Kyndryl Holdings, Inc. is under investigation for potential violations of U.S. federal securities laws, following a review of its cash management practices and internal controls, which has led to significant executive departures and a sharp decline in stock price [1]. Company Overview - Kyndryl is a provider of information technology infrastructure services [1]. Recent Developments - On February 9, 2026, Kyndryl announced that its Audit Committee is reviewing cash management practices and related disclosures, prompted by voluntary document requests from the SEC [1]. - The review has delayed the finalization of the Quarterly Report and the assessment of internal controls over financial reporting [1]. - Key executives, including the Chief Financial Officer David Wyshner and General Counsel Edward Sebold, have departed from the company, along with Senior Vice President and Global Controller Vineet Khurana, who has assumed a different role [1]. Market Reaction - Following the announcement of the investigation and executive changes, Kyndryl's stock price fell nearly 55% [1].

Core Viewpoint - Kyndryl Holdings, Inc. is under investigation for potential violations of federal securities laws, particularly concerning its cash management practices and financial reporting controls [1][3]. Company Overview - Kyndryl is a leading provider of enterprise technology services, offering advisory, implementation, and managed service capabilities across more than 60 countries [2]. - It is recognized as the world's largest IT infrastructure services provider [2]. Investigation Details - The investigation by Bleichmar Fonti & Auld LLP focuses on whether Kyndryl misrepresented its cash management practices and the drivers of its adjusted free cash flow metric for FY2025 and the first three quarters of FY2026 [3]. - The inquiry is prompted by concerns regarding the efficacy of Kyndryl's internal controls over financial reporting [3]. Stock Performance - On February 9, 2026, Kyndryl announced a delay in releasing its fiscal Q3 2026 financial statement due to an accounting review related to its cash management practices, which led to a stock price drop of over 52% during trading on the same day [4][5].

Core Viewpoint - Hub Group Inc. is under investigation for potential violations of federal securities laws, specifically regarding misrepresentation of transportation costs and accounts payable for the first nine months of 2025 [2]. Company Overview - Hub Group is a major supply chain solutions provider in North America, specializing in transportation and logistics management services [2]. Investigation Details - The investigation by Bleichmar Fonti & Auld LLP focuses on whether Hub Group misrepresented its financial data, particularly its purchased transportation costs and accounts payable [2]. - The firm is encouraging investors to seek additional information regarding their legal options [5]. Stock Performance - Hub Group's stock experienced a significant decline of over 24% on February 6, 2026, following the announcement of a delay in the release of its fourth quarter and full year 2025 financial results [4]. - The company announced it would restate its financial statements for the first three quarters of 2025 due to an error that understated purchased transportation costs and accounts payable [3].

Core Viewpoint - A class action lawsuit has been filed against Plug Power Inc. and certain senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1][3]. Company Overview - Plug Power specializes in hydrogen fuel cell turnkey solutions for electric mobility and stationary power markets, and develops infrastructure such as hydrogen production plants [4]. Legal Proceedings - Investors have until April 3, 2026, to request to lead the case, which is pending in the U.S. District Court for the Northern District of New York, captioned Ortolani v. Plug Power Inc., et al., No. 1:26-cv-00165 [3]. Allegations - The lawsuit claims that Plug Power materially overstated the likelihood of receiving a $1.66 billion loan guarantee from the U.S. Department of Energy, which was intended to finance the construction of hydrogen production facilities [4]. Stock Performance - On October 7, 2025, Plug Power's stock dropped by $0.26 per share (6.3%) following the announcement of the abrupt departure of its CEO and President [5]. - On November 10, 2025, the stock fell by $0.09 per share (3.4%) after the company suspended activities under the DOE loan program [6]. - A further decline occurred on November 14, 2025, when the stock dropped by $0.48 per share (17.6%) after reports confirmed the suspension of plans to construct hydrogen production facilities, jeopardizing the $1.66 billion DOE loan [7].